Continuous kidney therapy may be better than intermittent therapy
A trial found that intermittent hemodialysis was associated with higher mortality in critically ill patients with acute kidney injury.
Continuous renal-replacement therapy was linked to lower mortality than intermittent hemodialysis. This study looked at critically ill adults with acute kidney injury.
Researchers randomly assigned 554 patients to receive either intermittent hemodialysis or continuous renal-replacement therapy as their initial treatment. The primary outcome was a major adverse kidney event by day 90.
A major adverse kidney event is defined as death, dependence on renal-replacement therapy, or a serum creatinine concentration more than 25% above the baseline value. Acute kidney injury is a condition requiring renal-replacement therapy.
The trial stopped early because interim analyses showed a sustained signal of higher mortality with intermittent hemodialysis. In the intermittent group, 63.1% of 164 patients died by day 90. In the continuous group, 53.5% of 147 patients died by day 90.
Major adverse kidney events occurred in 78.1% of the intermittent group and 71.6% of the continuous group. The most common complication potentially related to the injury or therapy was hypotension.
Key facts
- Intermittent hemodialysis was not shown to be noninferior to continuous renal-replacement therapy.
- The 90 day mortality estimate was 63.3% for the intermittent group and 53.6% for the continuous group.
- Hypotension was the most common complication potentially related to the kidney injury or therapy.